⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28153885 | 0.90 | TSHR (0.35) | — | |
| SCHEMBL7044197 | 0.84 | — | — | |
| SCHEMBL29257278 | 0.83 | — | — | |
| SCHEMBL4868123 | 0.82 | TSHR (0.36) | — | |
| SCHEMBL10385442 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL2728498 | 0.77 | ALDH1A1 (0.46) | — | |
| SCHEMBL6444644 | 0.76 | — | — | |
| SCHEMBL10396286 | 0.75 | — | — | |
| SCHEMBL10621157 | 0.74 | — | — | |
| SCHEMBL2634415 | 0.73 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377844-B | Dioxopyrrolidine acetic acid derivative, preparation method and application thereof | 南京农业大学 | 2023-03-17 | — | — | CN | claimed |
| CN-111377844-A | Dioxopyrrolidine acetic acid derivative, preparation method and application thereof | 南京农业大学 | 2020-07-07 | — | — | CN | claimed |
| EP-1720840-B1 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2016-02-03 | — | — | EP | claimed |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | claimed |
| US-7785839-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2010-08-31 | — | — | US | claimed |
| EP-1720840-A4 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2009-01-21 | — | — | EP | claimed |
| CN-101044122-A | Process for preparing 1, 3-dioxolane nucleosides | UNIV EMORY (US) | 2007-09-26 | — | — | CN | claimed |
| EP-1720840-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2006-11-15 | — | — | EP | claimed |
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | SZNAIDMAN MARCOS | 2006-02-16 | — | — | US | claimed |
| WO-2005074654-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2005-08-18 | — | — | WO | claimed |
| US-20230365523-A1 | PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES | FIRMENICH SA (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116018334-A | Process for preparing 3- (cyclohex-1-en-1-yl) propanal derivatives | 弗门尼舍有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-4153552-A2 | PROCESS AND INTERMEDIATES FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL) PROPANAL DERIVATIVES | Firmenich SA (CH) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022049036-A2 | PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES | FIRMENICH SA (CH) | 2022-03-10 | — | — | WO | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
| US-6274589-B1 | VIRICIDES TO TREAT EPSTEIN-BARR, VARICELLA-ZOSTER, AND/OR HERPES INFECTIONS; KAPOSI'S SARCOMA | YALE UNIVERSITY | 2001-08-14 | — | — | US | disclosed |
| US-6022876-A | KAPOSI'S SARCOMA; VARICELLA-ZOSTER VIRUS | YALE UNIVERSITY (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0956021-A1 | L-$g(b)-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5792773-A | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection | YALE UNIVERSITY (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1998020879-A1 | L-β-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1998-05-22 | — | — | WO | disclosed |